Aridis Pharmaceuticals Inc. (ARDS) News

Aridis Pharmaceuticals Inc. (ARDS)

Today's Latest Price: $7.02 USD

0.28 (-3.84%)

Updated Jun 3 6:55pm

Add ARDS to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

Filter ARDS News Items

ARDS News Results

Event/TimeSymbolCompanyNews DetailStartEndChangePOWR Rating
Loading, please wait...

Latest ARDS News From Around the Web

Below are the latest news stories about Aridis Pharmaceuticals Inc that investors may wish to consider to help them evaluate ARDS as an investment opportunity.

Aridis Pharmaceuticals Announces First Quarter 2020 Results

Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, today reported financial and corporate results for the first quarter ended March 31, 2020.

Yahoo | May 12, 2020

Will Aridis Pharmaceuticals Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor Aridis Pharmaceuticals

Yahoo | May 7, 2020

Aridis Pharmaceuticals Enrolls Its First COVID-19 Patient in Ongoing Phase 3 AR-301 Clinical Trial in Ventilator Associated Pneumonia (VAP)

Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, announced today the enrollment of its first COVID-19 patient in the Company's ongoing Phase 3 clinical trial of AR-301, a monoclonal antibody against S. aureus induced pneumonia in patients who were already on mechanical ventilators.

Yahoo | May 4, 2020

Aridis Pharmaceuticals to Participate in Maxim Group's Infectious Disease Virtual Conference

Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, announced today its participation in Maxim Group's Infectious Disease Virtual Conference being held on May 5, 2020. Vu Truong, Ph.D., Chief Executive Officer, will be a speaker on two panels entitled "Non-antibiotic Anti-infectives" and "COVID-19 (Therapeutics)."

Yahoo | April 29, 2020

Can Aridis Pharmaceuticals’ APEX Platform Be Used to Target Coronavirus? Analyst Weighs In

If nothing else, the COVID-19 pandemic has spurred vast cooperation in the healthcare space. Having said that, it remains unclear as to what approach will be the most effective in stopping the deadly virus from continuing its romp around the world.Antiviral treatments such as remdesivir have garnered substantial attention, and while they are certainly promising with respect to their potential to slow the virus down, they won’t necessarily be able to stop COVID-19's spread completely. As was the case with other viral outbreaks like H1N1 in 2009 and Ebola in 2014, some healthcare officials argue that immune-based therapies like monoclonal antibody (mAb) cocktails and vaccines are our best bet.Enter Aridis Pharmaceuticals (ARDS), which is already up 37% year-to-date. Maxim analyst Jason Mc...

Yahoo | April 15, 2020

Aridis Pharmaceuticals Announces 2019 Fourth Quarter and Year-End Financial Results and Business Update

SAN JOSE, Calif., April 8, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, today reported financial and corporate…

PR Newswire | April 8, 2020

Aridis Pharmaceuticals to Postpone Investor Day Due to Coronavirus Concerns

Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, announced today the postponement of its Investor Day scheduled for Thursday, March 12th, 2020 to a future date due to concerns related to the coronavirus (COVID-19).

Yahoo | March 6, 2020

Aridis Pharmaceuticals to Present at the 32nd Annual ROTH Conference

Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, announced today that Vu Truong, Ph.D., Chief Executive Officer, will present at the 32nd Annual ROTH Conference on Monday, March 16, 2020 at 4:00 pm PDT. The conference will be held at The Ritz Carlton, Laguna Niguel in Orange County, CA.

Yahoo | March 5, 2020

Aridis Pharmaceuticals Provides Update on Investor Day Featuring Key Opinion Leader Panels on Cystic Fibrosis and Pneumonia

Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, is pleased to provide an update on its Investor Day being held on Thursday, March 12th, 2020 in New York City from 12:00PM-2:00PM EDT.

Yahoo | March 4, 2020

San Jose biotech incubator where Impossible Foods hatched expands at new site

In addition to Impossible Foods, the incubator was an early home to three companies that were acquired by Swiss pharma giant Roche Holdings — Ariosa Diagnostics, Genia Technologies and Geneweave. Another BioCube alumnus, Aridis Pharmaceuticals, went public in 2018.

Yahoo | February 28, 2020



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.5682 seconds.